Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00666575 · ClinicalTrials.gov registry record · Phase 3
A Study of the Safety of Gabapentin in a Potential Over-the-Counter Population With Occasional Sleeplessness
A Phase 3 study, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.
- Completed
- Registry status
- Phase 3
- Development phase
- 2,105
- Enrollment target
NCT00666575: Completed Phase 3 study, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.
NCT00666575 is a Phase 3 study that has completed, run by Pfizer's Upjohn has merged with Mylan to form Viatris. The registered enrollment target is 2,105 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (173% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00666575, a Phase 3 study, has completed, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2,105 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the safety of gabapentin, as compared to placebo, in a potential over-the-counter population with reports of occasional sleeplessness
Interventions
- DRUG Placebo
- DRUG Gabapentin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,105 participants |
| Start Date | 2004-12 |
| Est. Completion | 2005-05 |
| Phase | Phase 3 |
What the finished NCT00666575 record still lists
NCT00666575 is an interventional study that assigns participants to a tested intervention. Its 2,105 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (173% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00666575 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00666575 about?
NCT00666575 is a clinical study titled "A Study of the Safety of Gabapentin in a Potential Over-the-Counter Population With Occasional Sleeplessness". The purpose of this study is to assess the safety of gabapentin, as compared to placebo, in a potential over-the-counter population with reports of occasional sleeplessness
What is the current status of trial NCT00666575?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,105 participants. The study started on 2004-12. Estimated completion is 2005-05.
What interventions are being tested in trial NCT00666575?
The interventions under investigation include: Placebo (DRUG), Gabapentin (DRUG).
Who is sponsoring clinical trial NCT00666575?
This trial is sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris, which has 158 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00666575's enrollment target sits among peer trials
2,105 98th of 2000 higher than 1,903 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05967273 · 2,106 participants · NA
CirrhosisRx CDS System
- NCT04649242 · 2,100 participants · Phase 3
Randomized Study in Children and Adolescents With Migraine: Acute Treatment
- NCT05206331 · 2,100 participants · Phase 4
CEM to Reduce Biopsy Rates for Less Than Highly Suspicious Breast Abnormalities: a Prospective Study
- NCT05270499 · 2,100 participants
Aveir VR Real-World Evidence Post-Approval Study
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia